Indivior (NASDAQ:INDV) Sees Unusually-High Trading Volume

Indivior PLC (NASDAQ:INDV) saw an uptick in trading volume on Tuesday . 158,870 shares traded hands during mid-day trading, a decline of 50% from the previous session’s volume of 319,397 shares.The stock last traded at $9.51 and had previously closed at $10.02.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on INDV shares. Piper Sandler assumed coverage on Indivior in a research report on Tuesday, July 23rd. They set an “overweight” rating and a $22.00 target price on the stock. Craig Hallum dropped their price objective on Indivior from $37.00 to $24.00 and set a “buy” rating on the stock in a report on Wednesday, July 10th.

Indivior Stock Down 1.0 %

The company has a quick ratio of 0.68, a current ratio of 0.85 and a debt-to-equity ratio of 23.50. The stock has a 50-day simple moving average of $12.12 and a two-hundred day simple moving average of $16.48. The firm has a market cap of $1.32 billion, a PE ratio of 958.00 and a beta of 0.68.

Indivior (NASDAQ:INDV) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.40 by $0.04. The company had revenue of $299.00 million for the quarter, compared to analysts’ expectations of $285.90 million. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%. Analysts expect that Indivior PLC will post 1.74 earnings per share for the current year.

Institutional Trading of Indivior

Several institutional investors have recently added to or reduced their stakes in INDV. Norges Bank bought a new stake in shares of Indivior in the 4th quarter valued at about $36,011,000. Toronto Dominion Bank lifted its position in Indivior by 58.0% in the first quarter. Toronto Dominion Bank now owns 2,094,865 shares of the company’s stock valued at $44,872,000 after purchasing an additional 769,000 shares during the last quarter. UBS Group AG boosted its stake in shares of Indivior by 71.9% during the fourth quarter. UBS Group AG now owns 826,130 shares of the company’s stock valued at $12,615,000 after purchasing an additional 345,556 shares during the period. Lingotto Investment Management LLP grew its holdings in shares of Indivior by 115.7% in the fourth quarter. Lingotto Investment Management LLP now owns 590,000 shares of the company’s stock worth $8,913,000 after purchasing an additional 316,435 shares during the last quarter. Finally, Susquehanna International Group Ltd. purchased a new position in shares of Indivior in the second quarter worth $3,224,000. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.